TCG
GILD icon

Transcendent Capital Group’s Gilead Sciences GILD Stock Holding History

Transcendent Capital Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,893
Closed -$432K – 122
2025
Q2 		$432K Buy
+3,893
New +$414K 0.22% 75
2025
Q1 		– Sell
-137
Closed -$12.7K – 203
2024
Q4 		$12.7K Hold
137
– – 0.01% 323
2024
Q3 		$11.5K Hold
137
– – 0.01% 351
2024
Q2 		$9.4K Hold
137
– – 0.01% 326
2024
Q1 		$10K Hold
137
– – 0.01% 327
2023
Q4 		$11.1K Buy
+137
New +$10.7K 0.01% 262

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Transcendent Capital Group's GILD Position: Q3 2025 in Review

Transcendent Capital Group sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 3,893 shares — an estimated $432K sold.

Transcendent Capital Group first reported a position in GILD in Q4 2023 and held it in 6 quarters. The position peaked at $432K in Q2 2025. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Transcendent Capital Group reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Transcendent Capital Group sold 3,893 Gilead Sciences shares in Q3 2025, an estimated $432K.
  • Transcendent Capital Group first reported a position in Gilead Sciences in Q4 2023 and held it in 6 quarters.
  • Transcendent Capital Group's Gilead Sciences position peaked at $432K in Q2 2025.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Transcendent Capital Group's 13F filing for Q3 2025, filed 4 Nov 2025.